Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy
申请人:Klinge Pharma GmbH
公开号:US20020160968A1
公开(公告)日:2002-10-31
New biologically active compounds are described which inhibit the cellular formation of niacinamide mononucleotide, and essential intermediate of the NAD(P) biosynthesis in the cell. These compounds can represent the active ingredient of a pharmaceutical composition for the treatment of cancers, leukaemias or for immunosuppression. Furthermore, screening methods are described as a tool for detecting the above active compounds, and for examination of a given cell type for its dependency on niacinamide as a precursor for NAD synthesis.
本文介绍了一些新的生物活性化合物,这些化合物可以抑制细胞内烟酰胺单核苷酸的形成,该物质是NAD(P)生物合成的必要中间体。这些化合物可以作为治疗癌症、白血病或免疫抑制的药物组合物的活性成分。此外,还介绍了筛选方法,用于检测上述活性化合物,并检查给定细胞类型对烟酰胺作为NAD合成前体的依赖性。